Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Combination therapies for the treatment of prostate cancer

Fred Saad, FRCS, MD, Centre Hospitalier de l’Université de Montréal, Montreal, Canada, talks on combination therapy for prostate cancer. There is yet to be an approved combination treatment regimen for prostate cancer, however, for metastatic castration-resistant prostate cancer (mCRPC), a study will be commencing using another PARP inhibitor (PARPi), niraparib, plus abiraterone, the details of which will be discussed at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022. In metastatic hormone-sensitive PC (mHSPC), a large pivotal study looking at improving survival through combing docetaxel and dialuramide demonstrated a clear advantage in overall survival (OS) for the combination versus docetaxel or androgen deprivation therapy (ADT) alone. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.